Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent - Kim
Executive Summary
Merck's acquisition of Schering-Plough won't close until the fourth quarter, but the drug maker is already wading through a pipeline review to determine which research programs will get a green light as part of the combined company and which ones might get shelved